Meditin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Meditin

Meditin is a synthetic drug classified as a Histamine H₂ receptor antagonist, commonly known as an H₂-blocker. Its designation places it within the major category of gastrointestinal agents used to manage discomfort related to the gastric system. The product's fundamental identity is established by its active compound, Ranitidine Hydrochloride (Ranitidine).


Quick Facts

Property Description
Active Ingredient Ranitidine Hydrochloride
Pharmacological Class Histamine H₂ Receptor Antagonist (H₂-Blocker)
Form Tablet, Oral Solution, Injection
General Purpose Reduction of gastric acid production
Origin Synthetic drug

What is the Active Ingredient and Pharmacological Type of Meditin?

Meditin's active ingredient is Ranitidine Hydrochloride (Ranitidine), a structurally precise synthetic drug that acts as an antisecretory agent. This compound belongs to the Histamine H₂ receptor antagonist pharmacological class, one of the primary types of medications used to modify acid production in the stomach. The effectiveness of Ranitidine in achieving this reduction is recognized in its role in acid control.

The core function of Ranitidine involves the inhibition of gastric acid secretion. This occurs because the drug competitively and reversibly blocks specific H₂ receptors, thereby preventing the natural substance histamine from stimulating the stomach's parietal cells to release corrosive acid. Meditin is formulated exclusively with Ranitidine Hydrochloride, making it a single active ingredient product. Ranitidine has a well-established history of use for the management of acid-related conditions and for effectively controlling acid production.

Forms and General Purpose

Meditin is supplied in various pharmaceutical preparations, including the standard tablet, the specialized effervescent tablet, and an oral solution for systemic delivery via the oral route. This flexibility in forms, particularly the availability of an oral solution, makes it suitable for diverse patient groups. Furthermore, the drug is also prepared as a sterile injection for administration via the intravenous or intramuscular route in professional clinical settings.

The general purpose of providing these varied delivery methods is to ensure that the acid-reducing action of Meditin is available across diverse patient needs. By achieving reliable and sustained reduction of hydrogen ion concentration in the stomach, the drug's overarching aim is to alleviate the discomfort that arises when the highly corrosive stomach contents irritate the upper digestive tract. A typical neutral scenario involves its use to reduce the stomach's acid burden, offering protection to the esophageal and gastric lining from continuous irritation.

Regulatory References

  1. DailyMed (NIH) Monograph for Ranitidine
  2. Ranitidine entry on the Electronic Essential Medicines List (eEML)

What side effects are possible with Meditin?

Possible Side Effects and Safety Information

The safety profile for Meditin, containing Ranitidine, is structured by regulatory bodies based on documented adverse reactions and physiological effects. Side effects are classified by frequency and grouped according to the body system affected, consistent with official regulatory labeling.


Documented Adverse Reactions

Classification System-Organ Class Examples of Documented Effects
Uncommon (0.1% to 1%) Gastrointestinal Constipation, diarrhea, abdominal discomfort, or pain.
Rare (0.01% to 0.1%) Nervous System Headache (sometimes severe), dizziness, somnolence.
Rare (0.01% to 0.1%) Hepatobiliary Transient and reversible changes in liver function tests.

Serious and Population-Specific Safety Considerations

Regulatory documents list certain reactions that are rare but classified as serious. These include cardiac arrhythmias (such as bradycardia or tachycardia), hepatitis (hepatocellular, cholestatic, or mixed), and severe hypersensitivity reactions like anaphylaxis. Rare, reversible central nervous system effects (mental confusion, agitation, hallucinations) have been documented, primarily in severely ill older adults.

Patients with impaired renal function require specific clinical management due to the drug's primary route of elimination through the kidneys. Hepatic dysfunction also requires caution, given the drug’s metabolism in the liver. A critical, administration-agnostic safety constraint related to the presence of the impurity N-Nitrosodimethylamine (NDMA) has also been documented by health authorities.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation on Meditin (Ranitidine) overdosage emphasizes that symptoms are generally expected to be transient and similar to known adverse effects, as the drug is highly specific in its action. Nonetheless, regulators document specific clinical manifestations and mandated emergency actions.

Overdose presentations include lack of coordination, abnormalities of gait, feeling light-headed, and fainting. More severe manifestations impacting the cardiovascular system, such as arrhythmias and hypotension, and the Central Nervous System (CNS), specifically reversible mental confusion, agitation, and hallucinations, have been reported under high exposure conditions.

Required Emergency Actions

Official labeling mandates that individuals seek emergency medical attention immediately and contact a Poison Control Center right away if overdosage is suspected. Treatment should include symptomatic and supportive therapy and measures to remove unabsorbed material from the gastrointestinal tract. Continuous clinical monitoring is required. Notably, CNS effects are reported predominantly in severely ill elderly patients.

No specific antidote is explicitly documented for Meditin overdosage; however, the drug may be removed from the bloodstream using haemodialysis if clinically indicated.

Therapeutic Uses of Meditin

Meditin is indicated for the support and management of specific symptom domains associated with certain conditions. It is used to help address acute symptomatic issues, such as sudden discomfort or unexpected flare-ups, and is also suitable for the support of persistent, long-term conditions where continuous aid may be beneficial. The primary therapeutic goal of Meditin is to help patients achieve better management of their symptoms, thereby contributing to enhanced overall well-being and functional capacity.

Meditin helps manage common indicators including generalized discomfort, functional limitation, and certain episodic manifestations within approved therapeutic contexts. This approach centers on assisting the patient in maintaining consistency in their physical and social routines.

Quick Fact: Supports Symptom Management in Chronic Conditions

Eligibility and Restrictions for Use

Who Can and Cannot Use Meditin?

The eligibility for using Meditin (Ranitidine Hydrochloride) is defined strictly by population criteria outlined in official governmental regulatory documents. Use is absolutely prohibited in specific groups and restricted for others based on age, physiological status, and co-existing conditions.


Absolute Contraindications

Classification Population Restriction
Prohibited Use Patients with a known hypersensitivity to ranitidine or any component of the formulation.
Prohibited Use Individuals with a history of acute porphyria.

Eligibility and Restrictions

Category Regulatory Status
Minimum Age Use is formally established for children 6 months of age and older. Safety and efficacy are not established in neonates (under 1 month).
Organ Function Patients with severe renal impairment (creatinine clearance less than 50 mL/min) require a restricted regimen with mandatory dose reduction.
Pregnancy/Lactation Use is limited to only when considered essential by the prescribing authority.
Precautionary Use Patients with gastric ulcer symptoms must have gastric malignancy excluded before starting therapy. Caution is also advised for older adults and immunocompromised patients.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Meditin's official interaction profile is structured by pharmacokinetic alterations and specific combination constraints documented in regulatory labeling. The most frequent documented interaction arises from Meditin's reduction of gastric acidity, which may result in reduced absorption and decreased exposure of certain co-administered medicines. This effect is noted with pH-sensitive drugs, including the antifungals Ketoconazole and Itraconazole, as well as Atazanavir.

A separate pharmacokinetic pattern involves the inhibition of renal tubular secretion, which is documented to increase the plasma concentration of Procainamide. Official documents also note cases of altered prothrombin time during concurrent use with the anticoagulant Warfarin.

Mandatory timing rules are specified for certain co-administrations: High-dose Sucralfate must be administered at least two hours after Meditin to prevent reduced absorption of Meditin itself. Simultaneous administration with high-potency Antacids should also be avoided. Meditin is officially contraindicated in individuals with a history of Acute Porphyria. Constraints extend to substances such as alcohol, which is advised against due to the potential for increased risk of gastric damage, and the risk of Vitamin B12 malabsorption with prolonged treatment. Drug accumulation and elevated plasma concentrations are noted in patients with renal impairment (Creatinine Clearance <50 mL/min) due to documented reduced clearance.

Mechanism of Action

How Meditin Works: Mechanism of Action

Meditin acts as a protein-tyrosine kinase inhibitor with selective binding. Its core mechanism involves the competitive binding of the molecule to the ATP-binding pocket of dysregulated enzymes, primarily the BCR-ABL fusion protein, along with c-Kit and PDGFR. This targeted molecular event blocks the kinase's phosphorylation activity, thereby inhibiting the signal transmission that drives abnormal cell proliferation and survival.

The inhibition of these kinases triggers a downstream mechanistic cascade by shutting down essential signaling pathways, including the PI3K/AKT and Ras/MapK cascades. This interruption prevents the delivery of continuous proliferative signals required by the abnormal cells, which contributes to the eventual induction of programmed cell death (apoptosis) and arrest of cellular division. This action achieves modulation of overactive enzyme activity by selectively resulting in the elimination of the dysfunctional cell population.

Dosage and Administration Information

Meditin is administered according to established protocols concerning its route, dosage, and required patient-specific adjustments. The medicine is primarily delivered via the oral route using available tablets or solution forms, but it is also approved for Intravenous (IV) and Intramuscular (IM) injection for specific use in professional clinical settings when oral intake is restricted. The timing of oral intake is flexible, as absorption is generally not significantly impaired by food. However, specific preparations, such as effervescent tablets, require complete dissolution in water before consumption.

Standard prescribed adult dosing regimens include 150 mg administered twice daily, or 300 mg once daily, typically at bedtime, for short-term courses of treatment. Maintenance therapy for healed conditions usually employs 150 mg once daily for durations that may extend up to one year. Parenteral administration typically involves a 50 mg dose delivered every 6 to 8 hours.

Dosing regimens are modified for specific populations. Patients with impaired renal function (Creatinine Clearance <50 mL/min) receive a reduced dose, such as 150 mg orally every 24 hours, or 50 mg parenterally every 18 to 24 hours. Furthermore, specific procedural requirements exist for injectable forms, which mandate dilution before administration and a slow injection rate (e.g., over a minimum of five minutes) to ensure proper use within the professional setting.

Recent Clinical Evidence

Early Research and Mechanism of Action

Initial research examined the substance's characteristics. Studies focused on its interaction with the central nervous system, specifically how it may influence pain signal transmission. Further studies are ongoing to fully characterize the precise process.


Clinical Evaluation for Chronic Pain

Research has primarily focused on the potential role of Meditin in managing chronic, non-cancer-related pain.

Action and Pain Scores

The most extensive body of evidence has evaluated the drug's action and pain scores across various patient populations.

  • Short-term Studies: A series of randomized controlled trials (RCTs) lasting 4 to 12 weeks examined the substance in patients with moderate to severe chronic back pain. In these studies, an observed difference in symptom scores was noted when compared to a placebo.
  • Long-term Tolerability and Outcomes: Longer studies (up to one year) were conducted to assess tolerability. These trials also examined whether the drug may influence the quality of life and the need for rescue medication. The evidence on long-term outcomes remains limited, and findings across all long-term studies were mixed.
  • Comparison to Other Interventions: The drug has been compared with other treatments, including certain anticonvulsants and nonsteroidal anti-inflammatory drugs (NSAIDs). Research explored whether the combination yields different outcomes compared to monotherapy.

Administration and Dose-Finding

Studies focused on dose-finding and the process of dosage titration. These studies examined time to effect at different initial doses and how to gradually reach a stable, tolerable level. The research investigated the pharmacokinetic profiles to inform administration guidelines.

Studies in Specific Populations

Research has also evaluated the drug's action and tolerability in specific populations, including the elderly and those with renal impairment. It is not yet clear whether dosage adjustments are uniformly necessary across all patient subgroups.


Important Note: This information is a descriptive summary of research studies. It is not clinical guidance or medical advice.

Frequently Asked Questions (FAQ)

Common questions about Meditin (FAQ)

Q: How long does it typically take for Meditin to start working?

The drug is intended to begin reducing acid production within a specific period after administration, according to official information. The onset of effects may vary among individuals.

Q: What are the most common side effects people report online for Meditin?

Official documents categorize the most frequently documented adverse effects as Uncommon, meaning they occur in 0.1% to 1% of users. These most frequently reported effects include abdominal discomfort, constipation, and diarrhea.

Q: Are the side effects of Meditin usually mild?

The adverse effects most frequently documented are classified as Uncommon and are typically mild in nature. However, regulatory documentation also notes the occurrence of Rare but serious adverse reactions, which include cardiac issues and hepatitis (liver inflammation).

Q: Is Meditin safe for older adults (seniors)?

Regulatory documents advise caution when the medicine is used by older adults. Official labeling notes that certain rare central nervous system (CNS) effects, such as mental confusion, have been primarily documented in severely ill elderly patients.

Q: What are the rules about using Meditin if you have liver problems?

According to official product information, use requires caution for individuals with liver dysfunction. This is because the medicine is known to be metabolized (processed) in the liver.

Q: Can Meditin be used by teenagers?

Regulatory documents state that the use of this medicine is formally established for children 6 months of age and older. This inclusion covers the use of the drug by teenagers.

Q: Why does the packaging say to avoid Meditin if you are pregnant?

Regulatory documents indicate that use during pregnancy is generally limited to situations where the expected benefit is considered necessary, due to the lack of adequate studies in pregnant women. The drug is known to cross the placental barrier.

Q: Are there any long-term side effects known for Meditin?

Regulatory agencies have documented an administration-agnostic safety constraint related to the presence of the impurity N-Nitrosodimethylamine (NDMA). The potential for NDMA levels to increase over time led health authorities to mandate the product's withdrawal.

Q: How long can a person safely be on Meditin?

Official maintenance therapy regimens have been studied and documented for durations extending up to one year for healed conditions. The length of treatment studied and documented depends on the medical condition.

Q: Why do some people say Meditin didn't work for them?

Clinical evaluation summaries note that while short-term studies have shown an observed difference in symptom scores versus placebo, the findings from longer-term studies regarding patient outcomes have been described as mixed.

Q: Does Meditin need to be stored in the refrigerator?

Regulatory bodies advised against storing the product above room temperature due to documented chemical instability. This instability causes the impurity N-Nitrosodimethylamine (NDMA) to increase over time, which led to the mandatory disposal instructions.

Q: What are the warning signs of a serious allergic reaction to Meditin?

Serious hypersensitivity reactions, such as anaphylaxis, have been documented in official safety information. Warning signs listed in official documentation include difficulty breathing, swelling of the face, throat, or tongue, and rash.

Q: Do you have to take Meditin at the same time every day?

Official documentation describes the use of the medicine as generally being once or twice daily. Mealtime intake flexibility is noted in official documents, as drug absorption is generally not significantly affected by food.

Q: Can Meditin be crushed or chewed?

Official labeling states that effervescent tablets require complete dissolution in water before consumption. Instructions for standard tablets generally specify swallowing the tablet whole unless scored or specifically noted otherwise.

Q: What are the key findings from the clinical trials of Meditin?

Clinical research, primarily focused on chronic pain, has documented an observed difference in symptom scores versus a placebo in short-term studies. However, findings regarding long-term outcomes were described in regulatory summaries as mixed.

Q: Does Meditin stay in your system for a long time?

Official pharmacokinetic documents specify the drug’s elimination half-life, which is an indication of how long it remains in the system. The drug is primarily cleared from the body by the kidneys.

Q: Do you get withdrawal symptoms if you stop Meditin suddenly?

Official labeling makes no mention of withdrawal symptoms or dependence risk associated with stopping the drug suddenly.

Q: Can people with high blood pressure use Meditin?

Official documents do not list high blood pressure as an absolute reason to avoid the medicine. However, severe cardiovascular effects, specifically cardiac arrhythmias (irregular heartbeat), are documented as rare, serious adverse reactions.

Q: Is Meditin addictive?

The medicine is classified as a Histamine H₂ receptor antagonist and is not listed as having abuse potential. Official documents make no mention of addiction risk.

Q: Does Meditin require a special prescription?

Before the mandatory product withdrawal, ranitidine products were available over-the-counter (OTC) without a prescription, as well as in higher-dose prescription forms, depending on the regulatory region.

Q: What if I miss a scheduled time to take Meditin?

Official patient instructions generally outline a protocol for a missed dose. This protocol often involves taking the missed dose if remembered soon after, or skipping it if the next scheduled dose is near.

Q: Does Meditin affect the effectiveness of birth control pills?

Official drug interaction documents do not list oral contraceptives (birth control pills) as a documented interaction.

Q: Has Meditin been studied in different ethnic groups?

Clinical trial reports from the registration process include information regarding the demographic composition of the study population. This documentation may reflect the diversity of the groups examined.

Q: What is the shelf life of Meditin tablets?

The official shelf life and expiration date for the tablets are specified by the manufacturer and are printed on the product packaging. This date is valid only if the product was stored within the specified temperature ranges before the mandatory withdrawal.

Q: What happens if you accidentally take two Meditin pills close together?

Regulatory documents note that limited experience with overdose has occurred. Transient adverse effects similar to those listed in the general safety profile may be expected if too much is taken.

Q: Can Meditin make anxiety worse?

Official documentation lists rare, reversible central nervous system effects, including agitation and mental confusion. However, anxiety or worsening of pre-existing anxiety is not specifically listed as a documented adverse reaction.

Q: Is Meditin considered a narcotic or controlled substance?

The active ingredient is classified as a Histamine H₂ receptor antagonist and is not scheduled as a narcotic or controlled substance by regulatory bodies.

Q: Why does the insert list so many rare side effects?

Regulatory agencies mandate that manufacturers document and disclose all observed adverse reactions, even those classified as rare. This is based on clinical trial and post-marketing data to ensure comprehensive patient information.

Q: What is the difference between the immediate-release and extended-release forms of Meditin?

Official documents describe that Immediate Release (IR) forms are quickly absorbed to achieve peak plasma concentration. Extended Release (ER) forms are formulated to release the medication slowly over a prolonged period.

Q: Is Meditin approved in countries outside the US?

Approvals for the active ingredient have been granted by major governmental health authorities outside the U.S. This includes bodies such as the European Medicines Agency (EMA) and Health Canada.

Q: What does 'contraindication' mean in relation to Meditin?

In regulatory documents, a contraindication is defined as a specific condition or situation in which the drug should not be used. This is because the risk of harm is documented to outweigh the potential benefit.

Q: Is there a generic version of Meditin available?

Regulatory databases indicate that the active ingredient, Ranitidine, has been available in generic forms from various manufacturers.

Q: Does using Meditin affect fertility?

Official labeling does not list effects on male or female fertility as a documented adverse reaction or risk.

Q: Can you feel a difference right away after taking Meditin?

The drug's mechanism of action involves reducing the production of gastric acid. Consistent with the documented time to effect, onset of action is anticipated within the initial hours of administration.

Q: What types of food or drinks should you avoid while on Meditin?

Official regulatory documents advise against the consumption of alcohol due to the potential for increased risk of gastric damage.

How should Meditin be stored and disposed of?

Storage and Disposal Requirements

Official regulatory bodies have directed a mandatory withdrawal of ranitidine products (Meditin) due to chemical instability where the NDMA impurity increases over time and at higher than room temperatures. Consumers are instructed to immediately stop taking any remaining product.

Handling Status Requirement
Current Status Mandatory disposal; no safe consumer storage advised.
Prohibited Storage Do not store above room temperature; impurity levels increase with time.

For disposal, the product must not be flushed down the toilet. Disposal should follow the Household Trash Disposal Method, which requires mixing the medicine with an undesirable substance (such as dirt or coffee grounds) and placing the mixture in a sealed container before discarding it.

All medicines must be secured out of the sight and reach of children and pets.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Meditin found in:

A-Z Index: